PTEN loss is present in approximately 15% to 20% of primary PCa cases and in 40% to 60% of cases upon disease progression, with greater frequency in ETS-rearranged cases, and has been associated with a higher tumor stage, metastasis, and recurrence [86,98,99,100,101]. This evidence concerns the gene PTEN and posterior cortical atrophy.